Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dr Reddy’s Laboratories ( (RDY) ) has issued an update.
On July 23, 2025, Dr. Reddy’s Laboratories announced its financial results for the quarter ending June 30, 2025. The company released unaudited consolidated and standalone financial results in accordance with both International Financial Reporting Standards (IFRS) and Indian Accounting Standards (Ind AS). This disclosure, following a board meeting, highlights the company’s commitment to transparency and regulatory compliance, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The overall stock score for Dr Reddy’s Laboratories is solid, driven primarily by strong financial performance, indicating robust growth and stable operations. However, technical analysis suggests bearish momentum, and the valuation indicates limited dividend income potential, which slightly dampens the overall score.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a prominent pharmaceutical company based in Hyderabad, India. It specializes in the development and manufacturing of generic medications, active pharmaceutical ingredients, and biosimilars, with a significant focus on the global healthcare market.
Average Trading Volume: 1,584,368
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.99B
See more data about RDY stock on TipRanks’ Stock Analysis page.